<DOC>
	<DOCNO>NCT02532179</DOCNO>
	<brief_summary>This open label trial mouse allergenic extract administer subcutaneous injection adult asthma mouse sensitivity . The study design evaluate : - safety therapy give injection - biomarkers immune response - whether therapy would effective treat allergic asthma .</brief_summary>
	<brief_title>Subcutaneous Immunotherapy Mouse Adults</brief_title>
	<detailed_description>The primary objective study assess treatment mouse subcutaneous immunotherapy ( SCIT ) , use per protocol allergenic extract dos , safe . This do determine rate related adverse event serious adverse event course treatment . Secondary objective include : - determination whether 24 week treatment mouse SCIT , use per protocol allergenic extract dos , induce 3-fold increase mouse-specific serum immunoglobulin E ( IgE ) - determination whether 24 week treatment mouse SCIT , use per protocol allergenic extract dos , induce change serum level mouse-specific immunoglobulin G ( IgG ) immunoglobulin subclass 4 ( IgG4 ) .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<criteria>INCLUSION CRITERIA Participants meet follow criterion eligible enrollment may reassess . Participants ineligible : Are pregnant lactating . Females must abstinent use medically acceptable birth control method throughout study ( e.g . oral , subcutaneous , mechanical , surgical contraception ) ; Can perform spirometry Screening ; Have asthma severity classification Recruitment severe persistent , use NAEPP classification , evidence least one following : Requires dose great 500 mcg fluticasone per day equivalent another inhaled corticosteroid ; Have receive 2 course oral parenteral corticosteroid within last 12 month ; Have treat depot steroid within last 12 month ; Have hospitalize asthma within 6 month prior recruitment ; Have lifethreatening asthma exacerbation require intubation , mechanical ventilation , result hypoxic seizure within 2 year prior recruitment . Do access phone ( need scheduling appointment ) ; Have receive allergen immunotherapy ( SLIT SCIT ) last 12 month prior recruitment plan initiate resume allergen immunotherapy study ; Have previously treat antiIgE therapy within 1 year recruitment ; Have receive investigational drug 30 day prior recruitment plan use investigational drug study ; Refuses sign Epinephrine Autoinjector Training Form . EXCLUSION CRITERIA Participants meet follow criterion eligible enrollment may reassess . Participants ineligible : Do primarily speak English ; Plan move area study period ; Have history idiopathic anaphylaxis anaphylaxis grade 2 high define per protocol ; Have unstable angina , significant arrhythmia , uncontrolled hypertension , history autoimmune disease , chronic immunological disease opinion investigator might interfere evaluation investigational agent pose additional risk participant ; Are use tricyclic antidepressant betaadrenergic blocker drug ( oral topical ) ; Have receive seasonal Flu ( Influenza ) Vaccine enrol December March .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>subcutaneous immunotherapy ( SCIT )</keyword>
	<keyword>glycerinated mouse allergenic extract</keyword>
	<keyword>mouse specific IgE</keyword>
	<keyword>mouse specific IgG IgG4</keyword>
	<keyword>mouse prick skin test wheal</keyword>
</DOC>